SI-BONE, Inc. (SIBN)
| Market Cap | 1.07B |
| Revenue (ttm) | 77.01M |
| Net Income (ttm) | -43.17M |
| Shares Out | 32.69M |
| EPS (ttm) | -1.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6 |
| Last Price | $32.26 |
| Previous Close | $32.53 |
| Change ($) | -0.27 |
| Change (%) | -0.83% |
| Day's Open | 32.27 |
| Day's Range | 31.46 - 32.64 |
| Day's Volume | 301,709 |
| 52-Week Range | 14.40 - 37.21 |
Si-Bone (SIBN) delivered earnings and revenue surprises of 2.63% and 7.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of SI-BONE (NASDAQ:SIBN) remained quited after the company reported Q1 results. Quarterly Results Earnings per share were up 21.28% year over year to ($0.37), which beat the estimate of ($0.39).
SANTA CLARA, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported fina...
SANTA CLARA, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced ...
SANTA CLARA, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic ana...
SANTA CLARA, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced ...
Si-Bone (SIBN) delivered earnings and revenue surprises of 6.67% and 0.43%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of SI-BONE (NASDAQ:SIBN) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 22.22% year over year to ($0.28), which beat the estima...
SANTA CLARA, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported fi...
SI-BONE (NASDAQ:SIBN) releases its next round of earnings this Monday, March 08. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.
SANTA CLARA, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced i...
Laura Francis to Become Chief Executive Officer; Jeff Dunn to Become Executive Chairman; and Tony Recupero to Become President.
Updated Blue Cross Blue Shield Association Evidence Rating Supports only Triangular Implants Updated Blue Cross Blue Shield Association Evidence Rating Supports only Triangular Implants
SANTA CLARA, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced t...
Humana is one of the 5 largest commercial payors in the U.S. and joins 36 other commercial health plans that offer coverage for the triangular iFuse Implant System only Humana is one of the 5 largest co...
SI-BONE, Inc. (SIBN) CEO Jeff Dunn on Q3 2020 Results - Earnings Call Transcript
SANTA CLARA, Calif. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported fi...
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SANTA CLARA, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced i...
SANTA CLARA, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN) (“SI-BONE”), a Silicon Valley-based medical device company focused on the development of implantable devices used in t...
SANTA CLARA, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN) (“SI-BONE”), a Silicon Valley-based medical device company focused on the development of implantable devices used in t...
SANTA CLARA, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced pr...
SANTA CLARA, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anat...
SANTA CLARA, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced toda...
SANTA CLARA, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announce...
SI-BONE is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
35 U.S. payers now cover iFuse exclusively 35 U.S. payers now cover iFuse exclusively
SI-BONE, Inc. (SIBN) CEO Jeff Dunn on Q2 2020 Results - Earnings Call Transcript
Si-Bone (SIBN) delivered earnings and revenue surprises of 31.25% and 48.20%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
SANTA CLARA, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported f...
SANTA CLARA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced...
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SANTA CLARA, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced...
SANTA CLARA, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic an...
New positive coverage policy further validates acceptance of iFuse as an important treatment option for patients with chronic sacroiliac joint dysfunction
SI-BONE, Inc. (SIBN) CEO Jeff Dunn on Q1 2020 Results - Earnings Call Transcript
Si-Bone (SIBN) delivered earnings and revenue surprises of -30.56% and -6.45%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
SANTA CLARA, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported fi...
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SI-BONE, Inc. (SIBN) CEO Jeff Dunn on Q4 2019 Results - Earnings Call Transcript
New positive coverage policy is specific for FDA cleared implants placed across the SI joint and intended to promote bone fusion New positive coverage policy is specific for FDA cleared implants placed ...
SANTA CLARA, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic an...
SI-BONE, Inc.'s (SIBN) CEO Jeff Dunn on Q3 2019 Results - Earnings Call Transcript
Long-term follow-up results show excellent durability of clinical responses and positive radiographic outcomes for SI joint fusion using triangular titanium implants Long-term follow-up results show exc...
SANTA CLARA, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced...
SI-BONE, Inc. (SIBN) CEO Jeff Dunn on Q2 2019 Results - Earnings Call Transcript
SI-BONE's (SIBN) CEO Jeff Dunn on Q1 2019 Results - Earnings Call Transcript
About SIBN
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
| Industry Medical Devices | IPO Date Oct 17, 2018 |
| CEO Jeffrey Dunn | Employees 295 |
| Stock Exchange NASDAQ | Ticker Symbol SIBN |
Financial Performance
In 2020, SI-BONE, Inc.'s revenue was $73.39 million, an increase of 9.04% compared to the previous year's $67.30 million. Losses were -$43.70 million, 13.8% more than in 2019.
Analyst Forecasts
According to 7 analysts, the average rating for SI-BONE, Inc. stock is "Strong Buy." The 12-month stock price forecast is 41.29, which is an increase of 27.99% from the latest price.